Retinoic Acid–Functionalized Lipid Nanoparticles Reprogram Splenic Immunity for Potent mRNA Cancer Vaccination
Advanced Functional Materials · 2026-08 · 36 (66)
DOI: 10.1002/adfm.77225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Functional Materials, online erschienen am 22.07.2026. Verfasst von Ting Pan und 7 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Lipid nanoparticle (LNP)–enabled messenger RNA (mRNA) vaccines hold great promise for cancer immunotherapy, yet their clinical translation is often limited by insufficient delivery to secondary lymphoid organs and limited immune activation. Here, we design a redox‐responsive, all‐trans‐retinoic acid (ATRA)–functionalized PEG lipid (ATRA‐SS‐PEG, ASP) as a functional alternative to conventional DMG‐PEG for LNP formulation. ASP incorporation preserves LNP colloidal stability while promoting spleen‐oriented mRNA expression and efficient cytosolic release through intracellular redox‐triggered PEG shedding. Mechanistic comparison with a non‐cleavable ATRA‐PEG analogue confirms the functional contribution of the disulfide linkage to lysosomal escape and mRNA expression. ASP‐LNPs enhance splenic antigen expression, presentation, and immune activation, thereby reprogramming the splenic immune microenvironment toward effective immune priming. Notably, ASP‐LNPs maintain robust mRNA expression upon repeated administration, suggesting improved repeat‐dosing performance. As a proof of concept, ASP‐LNPs encoding ovalbumin (OVA) elicit potent antitumor immunity in B16‐OVA melanoma and pulmonary metastasis models, promoting effector T‐cell infiltration and suppressing tumor progression with a favorable safety profile. Collectively, this work establishes a spleen‐targeted and immunomodulatory LNP platform that integrates stimulus‐responsive cytosolic release with the intrinsic adjuvant activity of ATRA‐conjugated lipids, providing a versatile paradigm for next‐generation mRNA cancer vaccines.
Förderung
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Pan, T., Yin, S., Chu, R., Zhang, F., Yang, Y., Liu, J., Lu, Y., & He, J. (2026). Retinoic Acid–Functionalized Lipid Nanoparticles Reprogram Splenic Immunity for Potent mRNA Cancer Vaccination. Advanced Functional Materials, 36(66). https://doi.org/10.1002/adfm.77225
Vancouver
Pan T, Yin S, Chu R, Zhang F, Yang Y, Liu J, et al. Retinoic Acid–Functionalized Lipid Nanoparticles Reprogram Splenic Immunity for Potent mRNA Cancer Vaccination. Advanced Functional Materials. 2026;36(66). doi:10.1002/adfm.77225
BibTeX
@article{Pan2026,
author = {Pan, Ting and Yin, Shuqi and Chu, Runxuan and Zhang, Fan and Yang, Yani and Liu, Jie and Lu, Yi and He, Jun},
title = {Retinoic Acid–Functionalized Lipid Nanoparticles Reprogram Splenic Immunity for Potent mRNA Cancer Vaccination},
journal = {Advanced Functional Materials},
year = {2026},
volume = {36},
number = {66},
doi = {10.1002/adfm.77225}
}
EUVIMED